Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis

BACKGROUND: For children aged 6–11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo with an acceptable safety profile. However, longer-term safety and efficacy data are important to inform longi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cork, Michael J., Thaçi, Diamant, Eichenfield, Lawrence F., Arkwright, Peter D., Chen, Zhen, Thomas, Ryan B., Kosloski, Matthew P., Dubost-Brama, Ariane, Prescilla, Randy, Bansal, Ashish, Levit, Noah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613196/
https://www.ncbi.nlm.nih.gov/pubmed/37750994
http://dx.doi.org/10.1007/s13555-023-01016-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613196/
https://www.ncbi.nlm.nih.gov/pubmed/37750994
http://dx.doi.org/10.1007/s13555-023-01016-9

Ejemplares similares